What is the prognosis of stage I renal cell carcinoma according to the Surveillance, Epidemiology, and End Results (SEER) program?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Prognosis of Stage I Renal Cell Carcinoma

Stage I renal cell carcinoma has an excellent prognosis with a 5-year survival rate of approximately 95-96%, making it one of the most curable solid organ malignancies when detected at this early stage. 1, 2

Survival Outcomes by Stage

The prognosis for stage I RCC is substantially better than more advanced stages:

  • Stage I (tumor ≤7 cm, confined to kidney): 5-year survival of 91-96% 1, 2, 3
  • Stage II (tumor >7 cm, confined to kidney): 5-year survival of 72.8-88% 1, 2, 3
  • Stage III (locally advanced): 5-year survival of 55-67% 1, 3
  • Stage IV (metastatic): 5-year survival of 16.9-23% 1, 3

Cancer-Specific Survival Rates

The most recent AUA guidelines (2021) report cancer-specific survival rates of 80-90% at 5 years for clinically localized disease (Stage I-II), with Stage I representing the most favorable end of this spectrum. 1

More granular data demonstrates:

  • 5-year cancer-specific survival for Stage I: 77.8-91% 3, 4
  • The observed survival rate (accounting for all causes of death) is 81% for patients younger than 40 years and 64.2% for those older than 40 years 4

Prognostic Factors Beyond Stage

While stage is the primary determinant, several additional factors influence prognosis within Stage I disease:

Tumor Grade: Grade significantly stratifies survival even within Stage I 1, 3:

  • Grade 1: 5-year survival 77.8% 4
  • Grade 2: 5-year survival 69.6% 4
  • Grade 3-4: 5-year survival 35.3-48.8% 4

Tumor Size: Within the Stage I category, smaller tumors have better outcomes 5:

  • Tumors <4 cm: 5-year cancer-specific survival >94% with partial nephrectomy 5
  • Stage I includes tumors up to 7 cm, with larger tumors within this range having slightly worse prognosis 1

Mode of Detection: Incidentally detected tumors have superior outcomes 6:

  • Incidental Stage I tumors: 5-year cancer-specific survival 85.3% 6
  • Symptomatic Stage I tumors: Lower survival due to higher grade at presentation 6

Treatment Impact on Prognosis

Surgical intervention (partial or radical nephrectomy) for Stage I RCC achieves the excellent survival rates noted above, with partial nephrectomy being the preferred option for tumors <7 cm. 1, 2, 5

Important Clinical Caveats

  • Approximately 30% of recurrences occur after 5 years of treatment, necessitating long-term surveillance beyond the typical 5-year benchmark 1
  • The dramatic improvement in prognosis from Stage I to Stage IV underscores the critical importance of early detection 3, 4
  • Histologic subtype matters: The 95% survival figure primarily reflects clear cell RCC, which comprises 75-80% of cases 5
  • Performance status (ECOG) and tumor grade are independent prognostic factors that can modify outcomes within Stage I disease 3

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.